Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanz Pharma Agrees Sale In Largest European Deal Since COVID-19 Pandemic

Jefferies: ‘Deal Signals A Reduction Of Brexit Risk And A Recovery In The Debt Markets’

Executive Summary

Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.

You may also be interested in...



Advanz Appoints Stada Europe Head As New CEO

Stada’s head of Europe, Steffen Wagner, is set to become the new CEO of Advanz early next year, while current CEO Graeme Duncan will step down and take a new role as special advisor to the board. Advanz is also appointing a new chief financial officer, with Merck Healthcare’s Andreas Stickler set to succeed Adeel Ahmad in January.

Pharmathen Eyes US Growth As Owner Announces Sale

With plans to drive continuous innovation in drug administration technology and further implement state-of-the-art production capabilities, Swiss-based private equity Partners Group has announced a deal to acquire long-acting injectables specialist Pharmathen.

Nordic Completes $846m Takeover Of Advanz

Nordic Capital has completed its takeover of Advanz Pharma, three years after the company’s transformation from its former identity of Concordia. The company is planning “considerable investment” following the deal.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB150615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel